Skip to main content

Glipizide (Monograph)

Brand names: Glucotrol, Glucotrol XL
Drug class: Sulfonylureas
VA class: HS502
Chemical name: 1-cyclohexyl-3-[[p-[2-(5-methylpyrazine-carboxamido)ethyl]phenyl]sulfonyl]urea
Molecular formula: C21H27N5O4S
CAS number: 29094-61-9

Medically reviewed by Drugs.com on Jun 11, 2024. Written by ASHP.

Introduction

Antidiabetic agent; sulfonylurea.1 2 3

Uses for Glipizide

Type 2 Diabetes Mellitus

Used as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.1 2 3 19 27 50 51 52 53 54 55 56 57 58 59 60 95

Used in combination with one or more other oral antidiabetic agents or insulin as an adjunct to diet and exercise in patients who do not achieve adequate glycemic control with diet, exercise, and oral antidiabetic agent monotherapy.120 127 128 129 130 139 153 154 155 157 158 161 159 160 161 162 164

Used in fixed combination with metformin as initial therapy in patients with type 2 diabetes mellitus whose hyperglycemia cannot be controlled by diet and exercise alone and as second-line therapy in patients with type 2 diabetes mellitus who have inadequate glycemic control with either sulfonylurea or metformin monotherapy.153

Current guidelines for the treatment of type 2 diabetes mellitus generally recommend metformin as first-line therapy in addition to lifestyle modifications in patients with recent-onset type 2 diabetes mellitus or mild hyperglycemia due to its well-established safety and efficacy (e.g., beneficial effects on glycosylated hemoglobin [hemoglobin A1c; HbA1c], weight, and cardiovascular mortality).698 704 705

In patients with metformin contraindications or intolerance (e.g., risk of lactic acidosis, GI intolerance) or in selected other patients, some experts suggest that initial therapy with a drug from another class of antidiabetic agents (e.g., a glucagon-like peptide-1 [GLP-1] receptor agonist, sodium-glucose cotransporter 2 [SGLT2] inhibitor, dipeptidyl peptidase-4 [DPP-4] inhibitor, sulfonylurea, thiazolidinedione, basal insulin) may be acceptable based on patient factors.698 704

May need to initiate therapy with 2 agents (e.g., metformin plus another drug) in patients with high initial HbA1c (>7.5% or ≥1.5% above target).698 704 In such patients with metformin intolerance, some experts suggest initiation of therapy with 2 drugs from other antidiabetic drug classes with complementary mechanisms of action.698 704

Consider early initiation of combination therapy for the treatment of type 2 diabetes mellitus to extend the time to treatment failure and more rapidly attain glycemic goals.704

For patients with inadequate glycemic control on metformin monotherapy, consider patient comorbidities (e.g., atherosclerotic cardiovascular disease [ASCVD], established kidney disease, heart failure), hypoglycemia risk, impact on weight, cost, risk of adverse effects, and patient preferences when selecting additional antidiabetic agents for combination therapy.698 699 704 705 706

Consider early introduction of insulin for severe hyperglycemia (e.g., blood glucose of ≥300 mg/dL or HbA1c >9–10%), especially if accompanied by catabolic manifestations (e.g., weight loss, hypertriglyceridemia, ketosis) or symptoms of hyperglycemia.698 704

Manufacturer states that glipizide is not recommended for use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.95 707

Glipizide Dosage and Administration

General

Administration

Oral Administration

Administer extended-release or conventional (immediate-release) tablets once daily, generally with breakfast or the first main meal of the day.1 95 1 Administer conventional tablets approximately 30 minutes before a meal.1 11 32

Administer the fixed combination of glipizide and metformin once daily with a meal.153

Some patients may have a more satisfactory response when conventional tablets are administered in 2 or 3 divided doses daily.1 2 11 44 50 51 52 53 54 57 58 59 60 When dosage exceeds 15 mg daily as conventional tablets, administer in divided doses before meals of sufficient caloric content.1 2 59

Extended-release tablets should be swallowed whole and should not be divided, chewed, or crushed.95

Administer glipizide at least 4 hours prior to colesevelam when drugs given concomitantly.1 95 (See Specific Drugs under Interactions.)

Dosage

Adults

Type 2 Diabetes Mellitus
Initial Dosage in Previously Untreated Patients
Oral

Conventional or extended-release tablets: Initially, 5 mg daily.1 95 Titrate dosage of conventional tablets in increments of 2.5–5 mg daily at intervals of at least several days1 (usually 3–7 days).2 51 54 59 60 Maximum once daily dosage, 15 mg.1

For extended-release tablets, titrate dosage based on the patient's glycemic control.95

Initial Dosage in Patients Transferred from Conventional to Extended-release Glipizide Tablets
Oral

When transferring, administer the nearest equivalent total daily dosage of the extended-release tablets once daily.95

Initial Dosage in Patients Transferred from Other Oral Antidiabetic Agents
Oral

Individualize initial dosage of glipizide; usually 5–10 mg daily.90 92 The other oral antidiabetic agent may be discontinued abruptly; no transition period generally required.1 95

It has been recommended that patients being transferred from a sulfonylurea agent with a longer half-life (e.g., chlorpropamide [no longer commercially available in the US]) be closely monitored during the initial 1–2 weeks due to potential for overlapping drug effects.1 A drug-free interval of 2–3 days has been advised before glipizide therapy is initiated as conventional tablets in patients being transferred from chlorpropamide, particularly if blood glucose concentration was adequately controlled with chlorpropamide.90 92

Initial Dosage in Patients Transferred from Insulin
Oral

Insulin requirement ≤20 units daily: Initially, 5 mg of glipizide once daily.1 May discontinue insulin abruptly.1

Insulin requirement >20 units daily: Initially, 5 mg of glipizide once daily and reduce insulin dosage by 50%.1 Withdraw insulin gradually and adjust daily glipizide dosage at intervals of at least several days according to tolerance and response.1

Maintenance Dosage
Oral

Maintenance dosage varies considerably, ranging from 2.5–40 mg daily.1 2 7 27 39 40 41 42 43 44 50 51 52 53 54 56 57 58 59 60

Conventional tablets: Generally, 5–25 mg daily.27 39 40 41 42 43 44 50 51 52 53 54 56 57 58 59 60

Extended-release tablets: Generally, 5–10 mg daily.7 25 95

Combination Therapy with Other Oral Antidiabetic Agents
Oral

When added to therapy with other antidiabetic agents, may initiate glipizide extended-release tablets at a dosage of 5 mg daily.95 May use lower initial dosages in patients at risk for hypoglycemia.95

May initiate fixed combination of 2.5 mg of glipizide and 250 mg of metformin hydrochloride once daily with a meal in treatment-naive patients.153

For more severe hyperglycemia (i.e., fasting plasma glucose concentrations of 280–320 mg/dL), consider 2.5 mg of glipizide and 500 mg of metformin hydrochloride as fixed combination twice daily.153 Efficacy of fixed combination in patients with fasting plasma glucose concentrations >320 mg/dL not established.153

May increase dosage of fixed combination in increments of one tablet153 (using the tablet strength at which therapy was initiated, either 2.5 mg glipizide/250 mg metformin hydrochloride or 2.5 mg glipizide/500 mg metformin hydrochloride)163 daily every 2 weeks until the minimum effective dosage required to achieve adequate glycemic control is reached.153

Maximum daily dosage of fixed combination in treatment-naive patients is 10 mg of glipizide and 2 g of metformin hydrochloride given in divided doses.153

In previously treated patients with inadequate glycemic control on sulfonylurea (e.g., glipizide) or metformin monotherapy, initiate fixed-combination therapy with 2.5 mg of glipizide and 500 mg of metformin hydrochloride or 5 mg of glipizide and 500 mg of metformin hydrochloride twice daily with the morning and evening meals.153

To minimize hypoglycemia risk, do not exceed the initial daily dosage of glipizide or metformin hydrochloride already being taken.153

Titrate dosage upward in increments not exceeding 5 mg of glipizide and 500 mg of metformin hydrochloride until adequate glycemic control or a maximum daily dosage of 20 mg of glipizide and 2 g of metformin hydrochloride is reached in patients on sulfonylurea or metformin monotherapy.153

For patients being switched from therapy with both glipizide (or another sulfonylurea antidiabetic agent) and metformin, the initial dosage of the fixed-combination preparation should not exceed the daily dosages of glipizide (or equivalent dosage of another sulfonylurea) and metformin hydrochloride currently being taken.153 158 Monitor for signs and symptoms of hypoglycemia following the switch.153 In the transfer, base decision on whether to switch to the nearest equivalent dosage or to titrate dosage on clinical judgment.153

Prescribing Limits

Adults

Type 2 Diabetes Mellitus
Oral

Maximum once-daily dosage as conventional tablets is 15 mg.1

Maximum total daily dosage is 40 mg as divided doses of conventional tablets or 20 mg as extended-release tablets.1 95

Maximum total daily dosage of fixed combination in treatment-naive patients is 10 mg of glipizide and 2 g of metformin hydrochloride in divided doses.153

Maximum total daily dosage of fixed combination in patients with inadequate glycemic control on sulfonylurea and/or metformin therapy is 20 mg of glipizide and 2 g of metformin hydrochloride in divided doses.153

Special Populations

Hepatic Impairment

Conventional tablets: Initially, 2.5 mg daily;1 conservative maintenance dosage.1

Extended-release tablets: Use conservative initial and maintenance dosage.1

Adjust dosage carefully.1 27 71 95

Generally, do not use in patients with severe hepatic impairment.2 65 72

Renal Impairment

Use conservative initial and maintenance dosage.1 95

Use generally not recommended in patients with severe renal impairment.2 65 72

Cautious dosing recommended.

Geriatric Patients

Conventional tablets: Initially, 2.5 mg daily.1

Initially, 5 mg (extended-release tablets) may be used.1 95

Use conservative initial and maintenance dosage of glipizide-containing formulations.1 95 153

Adjust dosage carefully.1 Any dosage adjustment of glipizide in fixed combination with metformin hydrochloride requires careful assessment of renal function.153

Dosage of glipizide and metformin hydrochloride in fixed combination should not be titrated to the maximum dosage.

Debilitated or Malnourished Patients

Conservative initial and maintenance dosage of conventional and extended-release tablets.1 95

Dosage of glipizide and metformin hydrochloride in fixed combination should not be titrated to the maximum dosage.153

Detailed Glipizide dosage information

Cautions for Glipizide

Contraindications

Warnings/Precautions

Hypoglycemia

Reported infrequently; usually mild.2 27 50 58 59 60

Possible severe and/or prolonged hypoglycemia, especially in geriatric or malnourished patients and those with adrenal, pituitary, hepatic, or renal insufficiency.1 27 70 71 Strenuous exercise, alcohol ingestion (see Interactions), insufficient caloric intake, or use in combination with other antidiabetic agents (see Interactions) may increase hypoglycemia risk.1 Severe hypoglycemia can lead to unconsciousness or seizures; may result in temporary or permanent impairment of brain function or death.95

Appropriate patient selection and careful attention to dosage are important to avoid glipizide-induced hypoglycemia.

Loss of Glycemic Control

Possible loss of glycemic control during periods of stress (e.g., fever of any cause, trauma, infection, surgery).1 2

Temporary discontinuance of glipizide and administration of insulin may be required.1

Hematologic Effects

Hemolytic anemia may develop in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency who receive sulfonylureas; consider a non-sulfonylurea antidiabetic agent in patients with G6PD deficiency.1

Cardiovascular Effects

Possible increased cardiovascular mortality reported with other sulfonylurea antidiabetic agents (i.e., tolbutamide or phenformin).1 75 However, the American Diabetes Association (ADA) has stated that the benefits of intensive glycemic control with insulin or sulfonylureas outweigh the risks overall.97 107 113

Macrovascular Outcomes

Manufacturer states that no clinical studies have conclusively established macrovascular risk reduction with glipizide or any other antidiabetic drug.95

GI Obstruction

Use extended-release tablets with caution in patients with severe preexisting GI narrowing, since obstruction may occur.95

Use of Fixed Combinations

When use in fixed combination with metformin hydrochloride, consider the cautions, precautions, contraindications, and interactions associated with metformin.153

Specific Populations

Pregnancy

Category C.1

Sulfonylureas cross the placenta and have been associated with neonatal adverse reactions (e.g., hypoglycemia); prolonged, severe hypoglycemia reported in some neonates born to women receiving sulfonylureas up to time of delivery.95 Observe neonates for symptoms of hypoglycemia and respiratory distress and manage accordingly.95

Many experts recommend that insulin be used during pregnancy.1 95

Lactation

Not known whether glipizide is distributed into milk;1 discontinue nursing or the drug.1

If glipizide used during breast-feeding, monitor infants for signs of hypoglycemia (e.g., jitters, cyanosis, apnea, hypothermia, excessive sleepiness, poor feeding, seizures).95

Pediatric Use

Safety and efficacy not established.1 95 153 However, ADA has stated that most pediatric diabetologists use oral antidiabetic agents in children with type 2 diabetes mellitus because of greater compliance and convenience and lack of evidence demonstrating better efficacy of insulin for type 2 diabetes mellitus.117

Geriatric Use

Increased risk of hypoglycemia.1 27 71 95 Cautious and conservative dosing recommended.1 27 71 95 (See Geriatric Patients under Dosage and Administration.)

Hepatic Impairment

Increased risk of hypoglycemia.1 27 71 95 Cautious and conservative dosing recommended.1 27 71 95 (See Hepatic Impairment under Dosage and Administration.)

Avoidance in severe impairment has been recommended.2 65 72

Renal Impairment

Increased risk of hypoglycemia.1 27 71 Cautious and conservative dosing recommended.1 27 71 (See Renal Impairment under Dosage and Administration.)

Avoidance in severe impairment has been recommended.2 65 72

Common Adverse Effects

Conventional tablets: Nausea,1 50 anorexia,50 vomiting,50 pyrosis,50 gastralgia,1 diarrhea,1 constipation.1 2 50

Extended-release tablets: Dizziness,95 diarrhea,95 nervousness,95 tremor,95 hypoglycemia,95 flatulence.95

Glipizide/metformin hydrochloride fixed combination: Upper respiratory tract infection,95 diarrhea,95 dizziness,95 hypertension,95 nausea/vomiting,95 musculoskeletal pain,95 headache,95 abdominal pain,95 urinary tract infection.95 153

Drug Interactions

Protein-bound Drugs

Potential pharmacokinetic interaction with other protein-bound drugs.1 2 47 72 80

Use with caution with protein-bound drugs.1

Specific Drugs

Drug

Interaction

Comments

ACE inhibitors

May increase hypoglycemic effect95

Observe closely when concurrent therapy is initiated or discontinued95

Alcohol

May either potentiate or weaken hypoglycemic effect95

Rarely, disulfiram-like reactions1

Increase frequency of monitoring with concomitant administration95

Angiotensin II receptor antagonists

May increase hypoglycemic effect95

Observe closely when concurrent therapy is initiated or discontinued95

Antidiabetic agents

May increase hypoglycemic effect95

Observe closely when concurrent therapy is initiated or discontinued95

Antifungals, azole (e.g, fluconazole, miconazole, voriconazole)

Fluconazole increases plasma concentrations of glipizide1 95

Increased hypoglycemic effect1 95

Observe closely when concurrent therapy is initiated or discontinued1 95

Antipsychotics, atypical (e.g., clozapine, olanzapine)

May exacerbate hyperglycemia1 95

Observe closely when concurrent therapy is initiated or discontinued1 95

β-Adrenergic blocking agents

Impaired glucose tolerance; increased frequency or severity of hypoglycemia and hypoglycemia-induced complications62 72 80

May either potentiate or weaken hypoglycemic effect95

Reduced or absent signs of hypoglycemia95

If concomitant therapy is necessary, a β1-selective adrenergic blocking agent may be preferred62 72

Increase frequency of monitoring with concomitant administration95

Calcium-channel blocking agents

May exacerbate hyperglycemia1 95

Observe closely when concurrent therapy is initiated or discontinued1 95

Chloramphenicol

May increase hypoglycemic effect1 2 62 72 80 95

Observe closely when concurrent therapy is initiated or discontinued1 95

Clonidine

May either potentiate or weaken hypoglycemic effect95

Reduced or absent signs of hypoglycemia95

Increase frequency of monitoring with concomitant administration95

Colesevelam

Concomitant administration reduces glipizide AUC and peak plasma concentration by 12 and 13%, respectively1 95

Administer glipizide ≥4 hours prior to colesevelam1 95

Contraceptives, oral

May exacerbate hyperglycemia1 72 80 95

Observe closely when concurrent therapy is initiated or discontinued1 95

Corticosteroids

May exacerbate hyperglycemia1 72 80 95

Observe closely when concurrent therapy is initiated or discontinued1 95

Coumarins

Glipizide could displace or be displaced by oral anticoagulants (e.g., coumarins) from plasma protein binding sites;2 47 72 80 95 153 does not displace dicumarol from plasma protein binding sites in vitro1 81 82 95 153

May increase hypoglycemic effect95 95 153

Observe closely when concurrent therapy is initiated or discontinued1 95 153

Danazol

May exacerbate hyperglycemia95

Observe closely when concurrent therapy is initiated or discontinued95

Disopyramide

May increase hypoglycemic effect95

Observe closely when concurrent therapy is initiated or discontinued95

Diuretics (e.g., thiazides)

May exacerbate hyperglycemia1 72 80 84 95

Increased antidiabetic requirements1 72 80 84 95

Observe closely when concurrent therapy is initiated or discontinued1 95

Estrogens

May exacerbate hyperglycemia1 72 95

Observe closely when concurrent therapy is initiated or discontinued1 95

Fibric acid derivatives

May increase hypoglycemic effect95

Observe closely when concurrent therapy is initiated or discontinued95

Fluoxetine

May increase hypoglycemic effect95

Observe closely when concurrent therapy is initiated or discontinued95

Glucagon

May exacerbate hyperglycemia95

Observe closely when concurrent therapy is initiated or discontinued95

Guanethidine

Reduced or absent signs of hypoglycemia95

Increase frequency of monitoring with concomitant administration95

H2-receptor antagonists (e.g., cimetidine)

May increase hypoglycemic effect95

Cimetidine inhibits the hepatic metabolism of glipizide and potentiates hypoglycemic effect83

Observe closely when concurrent therapy is initiated or discontinued95

Glipizide dosage adjustment may be necessary when cimetidine is initiated or discontinued83

Hydantoins (e.g., phenytoin)

Glipizide could displace or be displaced by hydantoins from plasma protein binding sites2 47 72 80

May exacerbate hyperglycemia1 72 95

Observe closely when concurrent therapy is initiated or discontinued1 95

Isoniazid

May exacerbate hyperglycemia1 95

Observe closely when concurrent therapy is initiated or discontinued1 95

MAO inhibitors

Increases hypoglycemic effects1 2 72 80 95

Observe closely when concurrent therapy is initiated or discontinued1 95

Niacin

May exacerbate hyperglycemia1 95

Observe closely when concurrent therapy is initiated or discontinued1 95

NSAIAs

May increase hypoglycemic effect95

Glipizide could displace or be displaced by NSAIAs from plasma protein binding sites1 2 47 72 80

Observe closely when concurrent therapy is initiated or discontinued95

Pentoxifylline

May increase hypoglycemic effect95

Observe closely when concurrent therapy is initiated or discontinued95

Phenothiazines

May exacerbate hyperglycemia1 72 80 95

Observe closely when concurrent therapy is initiated or discontinued1 95

Pramlintide

Increases hypoglycemic effect95

Observe closely when concurrent therapy is initiated or discontinued95

Probenecid

Increases hypoglycemic effect1 72 80 95

Observe closely when concurrent therapy is initiated or discontinued1 95

Propoxyphene

May increase hypoglycemic effect95

Observe closely when concurrent therapy is initiated or discontinued95

Protease inhibitors

May exacerbate hyperglycemia95

Observe closely when concurrent therapy is initiated or discontinued95

Quinolones

May increase hypoglycemic effect95

Observe closely when concurrent therapy is initiated or discontinued95

Reserpine

May either potentiate or weaken hypoglycemic effect95

Reduced or absent signs of hypoglycemia95

Increase frequency of monitoring with concomitant administration95

Rifampin

May exacerbate hyperglycemia72 80

Salicylate

May increase hypoglycemic effect95

Does not displace salicylate from plasma protein binding sites1 81 82 95

Observe closely when concurrent therapy is initiated or discontinued95

Somatostatin analogs (e.g., octreotide)

May increase hypoglycemic effect95

Observe closely when concurrent therapy is initiated or discontinued95

Somatropin

May exacerbate hyperglycemia95

Observe closely when concurrent therapy is initiated or discontinued95

Sulfonamides

May increase hypoglycemic effect95

Glipizide could displace or be displaced by sulfonamides from plasma protein binding sites1 2 47 72 80

Observe closely when concurrent therapy is initiated or discontinued95

Sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline)

May exacerbate hyperglycemia1 72 95

Observe closely when concurrent therapy is initiated or discontinued1 95

Thyroid hormones

May exacerbate hyperglycemia1 72 80 95

Observe closely when concurrent therapy is initiated or discontinued1 95
Glipizide drug interactions (more detail)

Glipizide Pharmacokinetics

Absorption

Bioavailability

Absorption is essentially complete; 1 30 31 32 33 34 35 36 37 38 80–100% of an oral dose may be absorbed.30 31 95

Onset

Conventional tablets: 15–30 minutes.6 32 33

Duration

Conventional tablets: In nonfasting diabetic patients, the hypoglycemic action may persist for up to 24 hours.1 39 40 41 42 43 44

Food

Glipizide conventional tablets: Food delays absorption but does not affect peak serum concentrations or extent of absorption.32 33 Peak serum concentrations following administration of conventional tablets generally are delayed 20–40 minutes in the nonfasting state compared with the fasting state.1 32 33

Fixed combination of glipizide and metformin: Food delays peak plasma glipizide concentration by 1 hour.153

Glipizide extended-release tablets: Food does not affect glycemic response or time to absorption.95 Peak blood concentration following administration of extended-release tablets with food increased.95

Distribution

Extent

Following IV administration in mice, distributed into the liver and blood, with lower concentrations in the lungs, kidneys, adrenals, myocardium, salivary glands, and retroscapular fat.45 In humans, small amounts of glipizide are apparently distributed into bile30 34 37 and very small amounts are distributed into erythrocytes and saliva.30

Not known if glipizide is distributed into milk.1

Plasma Protein Binding

92–99%.30 34 36 46 95

Elimination

Metabolism

Appears to be almost completely metabolized, 30 34 35 36 37 mainly in the liver.1

Elimination Route

Glipizide and its metabolites are excreted principally in urine30 34 35 36 37 (60–90%) and to a lesser extent in feces (5–20%).30 34 35 37 95

95

Half-life

Terminal elimination half-life of glipizide averages 3–4.7 hours following oral administration in patients with normal renal and hepatic function.9 30 31 32 33 34 35 38 39 48

Terminal elimination half-life of total glipizide metabolites ranges from 2–6 hours.37

Special Populations

Renal or hepatic impairment may increase serum glipizide concentrations and reduce elimination.1 37 95

Severe renal impairment may decrease the renal excretion of and increase the terminal elimination half-life of glipizide metabolites.37 95

No differences in glipizide pharmacokinetics observed following single-dose administration to older diabetic patients compared with that in younger healthy individuals.95

Stability

Storage

Oral

Tablets (conventional)

Tight, light-resistant containers at 20–25°C.1 90

Tablets (extended-release)

20–25°C (may be exposed to 15–30°C); protect from moisture and humidity.95

Tablets (fixed-combination)

20–25°C (may be exposed to 15–30°C).153

Actions

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

glipiZIDE

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets

5 mg*

glipiZIDE Tablets

Glucotrol (scored)

Pfizer

10 mg*

glipiZIDE Tablets

Glucotrol (scored)

Pfizer

Tablets, extended-release

2.5 mg*

glipiZIDE Tablets ER

Glucotrol XL

Pfizer

5 mg*

glipiZIDE Tablets ER

Glucotrol XL

Pfizer

10 mg*

glipiZIDE Tablets ER

Glucotrol XL

Pfizer

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

glipiZIDE Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets, film-coated

2.5 mg with 250 mg Metformin Hydrochloride*

Glipizide with Metformin Hydrochloride Tablets

2.5 mg with 500 mg Meformin Hydrochloride*

Glipizide with Metformin Hydrochloride Tablets

5 mg with 500 mg Metformin Hydrochloride*

Glipizide with Metformin Hydrochloride Tablets

AHFS DI Essentials™. © Copyright 2024, Selected Revisions June 21, 2021. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

References

1. Pfizer. Glucotrol (glipizide) tablets prescribing information. New York, NY; 2016 Oct.

2. Brogden RN, Heel RC, Pakes GE et al. Glipizide: a review of its pharmacological properties and therapeutic use. Drugs. 1979; 18:329-53. http://www.ncbi.nlm.nih.gov/pubmed/389600?dopt=AbstractPlus

3. Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 1. Drugs. 1981; 22:211-45. http://www.ncbi.nlm.nih.gov/pubmed/7021124?dopt=AbstractPlus

4. Reynolds JEF, ed. Martindale: the extra pharmacopoeia. 28th ed. London: The Pharmaceutical Press; 1982:855.

5. Skillman TG, Feldman JM. The pharmacology of sulfonylureas. Am J Med. 1981; 70:361-72. http://www.ncbi.nlm.nih.gov/pubmed/6781341?dopt=AbstractPlus

6. Pisani Ceretti A, Losi S, Orsini G et al. A controlled study of the hypoglycemic and insulinopoietic effect of glipizide and glibenclamide in non-diabetic human subjects. Arzneimittelforschung. 1975; 25:675-6. http://www.ncbi.nlm.nih.gov/pubmed/808231?dopt=AbstractPlus

7. Greenfield MS, Doberne L, Rosenthal M et al. Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin-dependent diabetes mellitus. Diabetes Care. 1982; 31:307-12.

8. Reaven GM. Effect of glipizide treatment on various aspects of glucose, insulin, and lipid metabolism in patients with noninsulin-dependent diabetes mellitus. Am J Med. 1983; 75(Suppl. 5B):8-14. http://www.ncbi.nlm.nih.gov/pubmed/6369970?dopt=AbstractPlus

9. Peterson CM, Sims RV, Jones RL et al. Bioavailability of glipizide and its effect on blood glucose and insulin levels in patients with non-insulin-dependent diabetes. Diabetes Care. 1982; 5:497-500. http://www.ncbi.nlm.nih.gov/pubmed/6765225?dopt=AbstractPlus

10. Lebovitz HE, Feinglos MN. Mechanism of action of the second-generation sulfonylurea glipizide. Am J Med. 1983; 75(Suppl. 5B):46-54. http://www.ncbi.nlm.nih.gov/pubmed/6369967?dopt=AbstractPlus

11. Sartor G, Scherstén B, Melander A. Effects of glipizide and food intake on the blood levels of glucose and insulin in diabetic patients. Acta Med Scand. 1978; 203:211-4. http://www.ncbi.nlm.nih.gov/pubmed/345754?dopt=AbstractPlus

12. Feinglos MN, Lebovitz HE. Sulfonylurea treatment of insulin-independent diabetes mellitus. Metabolism. 1980; 29:488-94. http://www.ncbi.nlm.nih.gov/pubmed/6990184?dopt=AbstractPlus

13. Lebovitz HE, Feinglos MN, Bucholtz HK et al. Potentiation of insulin action: a probable mechanism for the anti-diabetic action of sulfonylurea drugs. J Clin Endocrinol Metab. 1977; 45:601-4. http://www.ncbi.nlm.nih.gov/pubmed/903405?dopt=AbstractPlus

14. Kolterman OG, Gray RS, Shapiro G et al. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes. 1984; 33:346-54. http://www.ncbi.nlm.nih.gov/pubmed/6423429?dopt=AbstractPlus

15. Gurwich EL (The Upjohn Company, Kalamazoo, MI): Personal communication; 1984 Jun 25.

16. DeFronzo RA, Ferrannini E, Koivisto V. New concepts in the pathogenesis and treatment of noninsulin-dependent diabetes mellitus. Am J Med. 1983; 74(Suppl. 1A):52-81. http://www.ncbi.nlm.nih.gov/pubmed/6337486?dopt=AbstractPlus

17. Lockwood DH, Maloff BL, Nowak SM et al. Extrapancreatic effects of sulfonylureas: potentiation of insulin action through post-binding mechanisms. Am J Med. 1983; 74(Suppl. 1A):102-8. http://www.ncbi.nlm.nih.gov/pubmed/6401922?dopt=AbstractPlus

18. Larner J. Mediators of postreceptor action of insulin. Am J Med. 1983; 74(Suppl. 1A):38-51. http://www.ncbi.nlm.nih.gov/pubmed/6297300?dopt=AbstractPlus

19. Fineberg SE, Schneider SH. Glipizide versus tolbutamide, an open trial: effects on insulin secretory patterns and glucose concentrations. Diabetologia. 1980; 18:49-54. http://www.ncbi.nlm.nih.gov/pubmed/6988265?dopt=AbstractPlus

20. Marco J, Valverde I. Unaltered glucagon secretion after seven days of sulphonylurea administration in normal subjects. Diabetologia. 1973; 9(Suppl.):317-9.

21. Serrano Rios M, Ordonez A, Sanchez MS et al. Long-term effects of glipizide on endocrine pancreas and insulin receptors in type 2 non-insulin-dependent diabetes. Diabetologia. 1983; 25:193-4.

22. Lecomte MJ, Luyckx AS, Lefebvre PF. Plasma glucagon and clinical control of maturity-onset type diabetes: effects of diet, placebo and glipizide. Diabete Metab. 1977; 3:239-43. http://www.ncbi.nlm.nih.gov/pubmed/340296?dopt=AbstractPlus

23. Best JD, Judzewitsch RG, Pfeifer MA et al. The effect of chronic sulfonylurea therapy on hepatic glucose production in non-insulin-dependent diabetes. Diabetes. 1982; 31:333-8. http://www.ncbi.nlm.nih.gov/pubmed/6759249?dopt=AbstractPlus

24. DeFronzo RA, Simonson DC. Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals. Diabetes Care. 1984; 7(Suppl. 1):72-80. http://www.ncbi.nlm.nih.gov/pubmed/6428844?dopt=AbstractPlus

25. Greenfield MS, Doberne L, Rosenthal M et al. Lipid metabolism in non-insulin-dependent diabetes mellitus: effect of glipizide therapy. Arch Intern Med. 1982; 142:1498-500. http://www.ncbi.nlm.nih.gov/pubmed/7103631?dopt=AbstractPlus

26. Bergman M, Gidez LI, Eder HA. The effect of glipizide on HDL and HDL subclasses. Diabetes. 1983; 32(Suppl. 1):157A.

27. Masbernard A, Giudicelli C, Massey J. Clinical experience with glipizide in the treatment of mostly complicated diabetes. Diabetologia. 1973; 9(Suppl.):356-63.

28. Preuss HG, Rodelas R, Terlinsky A et al. Effects of glipizide on water and electrolyte handling in water-loaded humans. Renal Physiol. 1981; 4:173-9. http://www.ncbi.nlm.nih.gov/pubmed/7302369?dopt=AbstractPlus

29. Gandini R, Cunietti E, Riario GG et al. Inhibition of aggregation of human platelets by glipizide in vitro. Diabetologia. 1982; 23:298.

30. Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics and pharmacodynamics of glipizide in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1983; 21:98-107. http://www.ncbi.nlm.nih.gov/pubmed/6341263?dopt=AbstractPlus

31. Wahlin-Boll E, Almer LO, Melander A. Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics. Clin Pharmacokinet. 1982; 7:363-72. http://www.ncbi.nlm.nih.gov/pubmed/7116738?dopt=AbstractPlus

32. Wahlin-Boll E, Melander A, Sartor G et al. Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy subjects. Eur J Clin Pharmacol. 1980; 18:279-83. http://www.ncbi.nlm.nih.gov/pubmed/7002565?dopt=AbstractPlus

33. Sartor G, Melander A, Scherstén B et al. Comparative single-dose kinetics and effects of four sulfonylureas in healthy volunteers. Acta Med Scand. 1980; 208:301-7. http://www.ncbi.nlm.nih.gov/pubmed/6778079?dopt=AbstractPlus

34. Fuccella LM, Tamassia V, Valzelli G. Metabolism and kinetics of the hypoglycemic agent glipizide in man—comparison with glibenclamide. J Clin Pharmacol. 1973; 13:68-75.

35. Balant L, Fabre J, Zahnd GR. Comparison of the pharmacokinetics of glipizide and glibenclamide in man. Eur J Clin Pharmacol. 1975; 8:63-9. http://www.ncbi.nlm.nih.gov/pubmed/823030?dopt=AbstractPlus

36. Schmidt HAE, Schoog M, Schweer KH et al. Pharmacokinetics and pharmacodynamics as well as metabolism following orally and intravenously administered C14-glipizide, a new antidiabetic. Diabetologia. 1973; 9(Suppl.):320-30.

37. Balant L, Zahnd G, Gorgia A et al. Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia. 1973; 9(Suppl.):331-8.

38. Huupponen R, Seppala P, Iisalo E. Glipizide pharmacokinetics and response in diabetics. Int J Clin Pharmacol Ther Toxicol. 1982; 20:417-22. http://www.ncbi.nlm.nih.gov/pubmed/6754633?dopt=AbstractPlus

39. Ostman J, Christenson I, Jansson B et al. The antidiabetic effect and pharmacokinetic properties of glipizide: comparison of a single dose with divided dose regime. Acta Med Scand. 1981; 210:173-80. http://www.ncbi.nlm.nih.gov/pubmed/7027750?dopt=AbstractPlus

40. Groop L, Harno K. Diurnal pattern of plasma insulin and blood glucose during glibenclamide and glipizide therapy in elderly diabetics. Acta Endocrinol Suppl. 1980; 239:44-52.

41. Benfield GFA, Pettengell KE, Hunter KR. Once-daily v twice daily glipizide in diabetes mellitus. Br J Clin Pharmacol. 1982; 14:614P.

42. Corrall RJM, Thornley P, Bhalla IP et al. Observations on the efficacy and safety of glipizide: a new low dosage sulphonylurea. Acta Ther. 1976; 2:77-88.

43. Azzopardi J, Campbell IW, Clarke BF et al. Duree de l’effet hypoglycemiant utile du glipizide administre une fois par jour a des malades atteints de diabete non insulino-dependant moderement severe. (French; with English abstract.) Acta Ther. 1975; 1:19-29.

44. Almer LO, Johansson E, Melander A et al. Influence of sulfonylureas on the secretion, disposal and effect of insulin. Eur J Clin Pharmacol. 1982; 22:27-32. http://www.ncbi.nlm.nih.gov/pubmed/7047169?dopt=AbstractPlus

45. Goldaniga GC, Maraone C, Pianezzola E et al. Metabolism of glipizide in the rat and dog and its tissue distribution in the mouse. Arzneimittelforschung. 1973; 23:242-6. http://www.ncbi.nlm.nih.gov/pubmed/4739837?dopt=AbstractPlus

46. Crooks MJ, Brown KF. Interaction of glipizide with human serum albumin. Biochem Pharmacol. 1975; 24:298-9. http://www.ncbi.nlm.nih.gov/pubmed/234237?dopt=AbstractPlus

47. Hsu PL, Ma JKH, Luzzi LA. Interactions of sulfonylureas with plasma proteins. J Pharm Sci. 1974; 63:570-3. http://www.ncbi.nlm.nih.gov/pubmed/4208196?dopt=AbstractPlus

48. MacWalter RS, El Debani AH, Feely J et al. Studies on glipizide pharmacokinetics and effect in diabetic patients. Br J Clin PHarmacol. 1984; 17:622-3P.

49. Tamassia V. Pharmacokinetics and bioavailability of glipizide. Curr Med Res Opin. 1975; 3(Suppl. 1):20-30.

50. Emanueli A, Molari E, Pirola LC et al. Glipizide, a new sulfonylurea in the treatment of diabetes mellitus: summary of clinical experience in 1064 cases. Arzneimittelforschung. 1972; 22:1881-5. http://www.ncbi.nlm.nih.gov/pubmed/4267009?dopt=AbstractPlus

51. De Leeuw I, De Baere H, Decraene P et al. An open comparative study of the efficacy and tolerance of a new antidiabetic agent: glipizide. Diabetologia. 1973; 9(Suppl.):364-6.

52. Parodi FA, Caputo G. Long-term treatment of diabetes with glipizide. Curr Med Res Opin. 1975; 3(Suppl. 1):31-6.

53. Bandisode MS, Boshell BR. Clinical evaluation of a new sulfonylurea in maturity onset diabetes—glipizide (K-4024). Horm Metab Res. 1976; 8:88-91.

54. Fowler LK. Glipizide in the treatment of maturity-onset diabetes: a multi-centre, out-patient study. Curr Med Res Opin. 1978; 5:418-23. http://www.ncbi.nlm.nih.gov/pubmed/350493?dopt=AbstractPlus

55. Feinglos MN, Lebovitz HE. Long-term safety and efficacy of glipizide. Am J Med. 1983; 75(Suppl. 5B):60-6. http://www.ncbi.nlm.nih.gov/pubmed/6369969?dopt=AbstractPlus

56. Adetuyibi A, Ogundipe OO. A comparative trial of glipizide, glibenclamide and chlorpropamide in the management of maturity-onset diabetes mellitus in Nigerians. Curr Ther Res. 1977; 21:485-90.

57. Blohmé G, Waldenstrom J. Glibenclamide and glipizide in maturity onset diabetes. Acta Med Scand. 1979; 206:263-7. http://www.ncbi.nlm.nih.gov/pubmed/116480?dopt=AbstractPlus

58. Frederiksen PK, Mogensen EF. A clinical comparison between glipizide (Glibenese) and glibenclamide (Daonil) in the treatment of maturity onset diabetes: a controlled double-blind cross-over study. Curr Ther Res. 1982; 32:1-7.

59. Shuman CR. Glipizide: an overview. Am J Med. 1983; 75(Suppl. 5B):55-9. http://www.ncbi.nlm.nih.gov/pubmed/6369968?dopt=AbstractPlus

60. Fuchs K. Glipizide versus tolbutamide in maturity-onset diabetes, an open comparative study. Diabetologia. 1973; 9(Suppl.):351-5.

61. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979; 28:1039-57. http://www.ncbi.nlm.nih.gov/pubmed/510803?dopt=AbstractPlus

62. Koda-Kimble MA. Diabetes mellitus. In: Koda-Kimble MA, Young LY, eds. Applied therapeutics: the clinical use of drugs. 5th ed. Vancouver, WA: Applied Therapeutics, Inc.; 1992:72–1-53.

63. Skyler JS. Non-insulin-dependent diabetes mellitus, a clinical strategy. Diabetes Care. 1984: 7(Suppl. 1):118-29.

64. Scientific Advisory Panel of the Executive Committee, American Diabetes Association. Policy statement: the UGDP controversy. Diabetes. 1979; 28:168-70.

65. Asmal AC, Marble A. Oral hypoglycaemic agents: an update. Drugs. 1984; 28:62-78. http://www.ncbi.nlm.nih.gov/pubmed/6378583?dopt=AbstractPlus

66. Lebovitz HE. Clinical utility of oral hypoglycemic agents in the management of patients with noninsulin-dependent diabetes mellitus. Am J Med. 1983; 75(Suppl. 5B):94-9. http://www.ncbi.nlm.nih.gov/pubmed/6369972?dopt=AbstractPlus

67. Allen BT, Feinglos MN, Lebovitz H. Combined insulin, glipizide treatment of non-insulin dependent diabetes mellitus. Diabetes. 1983; 32(Suppl. 1):35A.

68. Camerini-Davalos RA, Velasco C, Glasser M et al. Drug-induced reversal of early diabetic microangiopathy. N Engl J Med. 1984; 309:1551-6.

69. Siperstein MD. Diabetic microangiopathy and the control of blood glucose. N Engl J Med. 1983; 309:1577-9. http://www.ncbi.nlm.nih.gov/pubmed/6656851?dopt=AbstractPlus

70. Blohmé G, Branegard B, Fahlen M et al. Glipizide-induced severe hypoglycemia. Acta Endocrinol Suppl. 1981; 245:13.

71. Seltzer HS. Severe drug-induced hypoglycemia: a review. Compr Ther. 1979; 5(4):21-9. http://www.ncbi.nlm.nih.gov/pubmed/445986?dopt=AbstractPlus

72. Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2. Drugs. 1981; 22:295-320. http://www.ncbi.nlm.nih.gov/pubmed/7030708?dopt=AbstractPlus

73. American Diabetes Association. Policy statement: indications for use of continuous insulin delivery systems and self-measurement of blood glucose. Diabetes Care. 1982; 5:140-1.

74. Holmes B, Heel RC, Brogden RN et al. Gliclazide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. Drugs. 1984; 27:301-27. http://www.ncbi.nlm.nih.gov/pubmed/6373223?dopt=AbstractPlus

75. Food and Drug Administration. Labeling for oral hypoglycemic drugs of the sulfonylurea class. Docket No. 75N-0062 Fed Regist. 1984; 49:14303-31.

76. Renner HW, Munzer R. Mutagenicity of sulphonylureas. Mutat Res. 1980; 77:349-55. http://www.ncbi.nlm.nih.gov/pubmed/6990252?dopt=AbstractPlus

77. Krans HMJ. Insulin, glucagon and oral hypoglycaemic drugs. In: Dukes MNG, ed. Side effects of drugs. Annual 3. New York: Elsevier/North Holland Inc.; 1979:347.

78. Kannisto H, Neuvonen PJ. Adsorption of sulfonylureas onto activated charcoal in vitro. J Pharm Sci. 1984; 73:253-6. http://www.ncbi.nlm.nih.gov/pubmed/6707896?dopt=AbstractPlus

79. Neuvonen PJ, Karkkainen S. Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics. Clin Pharmacol Ther. 1983; 33:386-93. http://www.ncbi.nlm.nih.gov/pubmed/6297841?dopt=AbstractPlus

80. Hansten PD. Drug interactions. 4th ed. Philadelphia: Lea & Febiger; 1979:14, 93-109.

81. Melander A, Wahlin-Boll E. Interaction of glipizide and indoprofen. Eur J Rheumatol Inflammation. 1981; 4:22-5.

82. Pedrazzi F, Bommartini F, Freddo J et al. A study of the possible interaction of indoprofen with hypoglycemic sulfonylureas in diabetic patients. Eur J Rheumatol Inflammation. 1981; 4:26-31.

83. Feely J, Peden N. Enhanced sulphonylurea-induced hypoglycaemia with cimetidine. Br J Clin Pharmacol. 1983; 15:607P.

84. The Upjohn Company. Orinase prescribing information. In: Huff BB, ed. Physicians’ desk reference. 38th ed. Oradell, NJ: Medical Economics Company Inc.; 1984:2041-3.

85. Leslie RDG, Pyke DA. Chlorpropamide-alcohol flushing: a dominantly inherited trait associated with diabetes. Br Med J. 1978; 2:1519-21. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1608771&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/728707?dopt=AbstractPlus

86. Groop L, Totterman KJ. Propranolol does not inhibit sulphonylurea-stimulated insulin secretion in patients with non-insulin dependent diabetes mellitus. Acta Endocrinol. 1982; 100:410-5. http://www.ncbi.nlm.nih.gov/pubmed/7051722?dopt=AbstractPlus

87. Farr MJ. Diazoxide, glipizide, hypertension and hypoglycaemia. Lancet. 1976; 2:1138. http://www.ncbi.nlm.nih.gov/pubmed/62974?dopt=AbstractPlus

88. Kollind M, Adamson U, Lins PE et al. Influence of glipizide on xylose absorption in type II diabetes. Acta Endocrinol Suppl. 1982; 247:39.

89. Wahlin-Boll E, Sartor G, Melander A et al. Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharmacol. 1982; 22:21-5. http://www.ncbi.nlm.nih.gov/pubmed/7047168?dopt=AbstractPlus

90. Giorgianni SJ (Roerig; New York, NY): Personal communication; 1984 Sep.

91. Melander A, Wahlin-Boll E. Clinical pharmacology of glipizide. Am J Med. 1983; 75(Suppl. 5B):41-5. http://www.ncbi.nlm.nih.gov/pubmed/6424440?dopt=AbstractPlus

92. Reviewers’ comments (personal observations); 1984 Sep.

93. The Upjohn Company. Micronase prescribing information. Kalamazoo, MI; 1984 May.

94. Bergman M, Felig P. Self-monitoring of blood glucose levels in diabetes: principles and practice. Arch Intern Med. 1984; 144:2029-34. http://www.ncbi.nlm.nih.gov/pubmed/6385899?dopt=AbstractPlus

95. Pfizer Inc. Glucotrol XL(glipizide) extended release tablets prescribing information. New York, NY; 2018 Aug.

96. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-53. http://www.ncbi.nlm.nih.gov/pubmed/9742976?dopt=AbstractPlus

97. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 1999; 22(Suppl 1):S27-31.

98. Matthews DR, Cull CA, Stratton RR et al. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over 6 years. Diabet Med. 1998; 15:297-303. http://www.ncbi.nlm.nih.gov/pubmed/9585394?dopt=AbstractPlus

99. Genuth P. United Kingdom prospective diabetes study results are in. J Fam Pract. 1998; 47:(Suppl 5):S27.

100. Bretzel RG, Voit K, Schatz H et al. The United Kingdom Prospective Diabetes Study (UKPDS): implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 1998; 106:369-72. http://www.ncbi.nlm.nih.gov/pubmed/9831300?dopt=AbstractPlus

101. Schmitt JK, Moore JR. Hypertension secondary to chlorpropamide with amelioration by changing to insulin. Am J Hypertens. 1993; 6:317-9. http://www.ncbi.nlm.nih.gov/pubmed/8507452?dopt=AbstractPlus

102. Genuth S, Brownless MA, Kuller LH et al. Consensus development conference on insulin resistance: Novermber 5-6 1997. Diabetes Care. 1998; 21:310-4. http://www.ncbi.nlm.nih.gov/pubmed/9540000?dopt=AbstractPlus

103. Henry RR. Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996; 124:97-103. http://www.ncbi.nlm.nih.gov/pubmed/8554221?dopt=AbstractPlus

104. Lebovitz HE. Stepwise and combination drug therapy for the treatment of NIDDM. Diabetes Care. 1994; 17:1542-4. http://www.ncbi.nlm.nih.gov/pubmed/7882832?dopt=AbstractPlus

105. Nathan DM. Some answers, more controversy, from UKDS. Lancet. 1998; 352:832-3. http://www.ncbi.nlm.nih.gov/pubmed/9742972?dopt=AbstractPlus

106. Reviewers’ comments (personal observations) on metformin.

107. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002; 25(Suppl 1):S33-49.

108. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86. http://www.ncbi.nlm.nih.gov/pubmed/8366922?dopt=AbstractPlus

109. Klein R, Klein BEK, Moss SE et al. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA. 1988; 260:2864-71. http://www.ncbi.nlm.nih.gov/pubmed/3184351?dopt=AbstractPlus

110. American Diabetes Association. Implications of the diabetes control and complications trial. Diabetes Care. 1996; 19:50-2S.

111. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus; a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28:103-17. http://www.ncbi.nlm.nih.gov/pubmed/7587918?dopt=AbstractPlus

112. UK Prospective Diabetes Study (UKPDS) Group. ffect of intensive blood-glucose control with metfromin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352:854-65. http://www.ncbi.nlm.nih.gov/pubmed/9742977?dopt=AbstractPlus

113. American Diabetes Association. The United Kingdom Prospective Diabetes Study (UKPDS) for type 2 diabetes: what you need to know about the results of a long-term study. Washington, DC; September 15, 1998. From American Diabetes Association web site/ada/ukpds.asp). https://www.diabetews.org/ada/ukpds.asp)

114. Davis TM. United Kingdom Prospective Diabetes Study: the end of the beginning? Med J Aust. 1998; 169:511-2.

115. Watkins PJ. UKPDS: a message of hope and a need for change. Diabet Med. 1998; 15:895-6. http://www.ncbi.nlm.nih.gov/pubmed/9827842?dopt=AbstractPlus

116. Turner RC, Cull CA, Frighi V et al. Glycemic control with diet, sulfonlyurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirements for multiple therapies (UKPDS 49). JAMA. 1999; 281:2005-12. http://www.ncbi.nlm.nih.gov/pubmed/10359389?dopt=AbstractPlus

117. American Diabetes Association. Type 2 diabetes in children and adolescents. Pediatrics. 2000; 105:671-80. http://www.ncbi.nlm.nih.gov/pubmed/10699131?dopt=AbstractPlus

118. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2000; 23(Suppl 1):S4-19.

119. American Diabetes Association. Office guide to diagnosis and classification of diabetes mellitus and other categories of glucose intolerance. Diabetes Care. 1995; 18(Suppl 1):4.

120. Williams G. Management of non-insulin-dependent diabetes mellitus. Lancet. 1994; 343:95-100. http://www.ncbi.nlm.nih.gov/pubmed/7903785?dopt=AbstractPlus

121. Genuth S. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124(1 Part 2):104-9.

122. DeFronzo RA. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988; 37:667-87. http://www.ncbi.nlm.nih.gov/pubmed/3289989?dopt=AbstractPlus

123. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996; 334:777-83. http://www.ncbi.nlm.nih.gov/pubmed/8592553?dopt=AbstractPlus

124. Swislocki A. Insulin resistance and hypertension. Am J Med Sci. 1990; 300:104-15. http://www.ncbi.nlm.nih.gov/pubmed/2206054?dopt=AbstractPlus

125. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317:703-13. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=28659&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/9732337?dopt=AbstractPlus

126. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes mellitus: UKPDS 39. BMJ. 1998; 317:713-20. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=28660&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/9732338?dopt=AbstractPlus

127. Chow CC, Sorensen JP, Tsang LWW et al. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care. 1995; 18:307-14. http://www.ncbi.nlm.nih.gov/pubmed/7555472?dopt=AbstractPlus

128. Zimmerman B, Espenshade J, Fujimoto W et al. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care. 1995; 19:1510-18.

129. Expert Committee of the Canadian Diabetes Advisory Board. Clinical practice guidelines for treatment of diabetes mellitus. Can Med Assoc J. 1992; 147:697-712.

130. Raskin P. Combination therapy in NIDDM N Engl J Med. 1992; 327:1453-4. Editorial.

131. Landstedt-Hallin L, Bolinder J, Adamson U et al. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care. 1995; 18:1183-6. http://www.ncbi.nlm.nih.gov/pubmed/7587856?dopt=AbstractPlus

132. Buse J. Combining insulin and oral agents. Am J Med. 2000; 108(Suppl 6A):23S-32S. http://www.ncbi.nlm.nih.gov/pubmed/10764847?dopt=AbstractPlus

133. Trischitta V, Italia S, Mazzarino S et al. Comparison of combined therapies in treatment of secondary failure to glyburide. Diabetes Care. 1992; 15:539-42. http://www.ncbi.nlm.nih.gov/pubmed/1499473?dopt=AbstractPlus

134. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomized placebo-controlled trials. Arch Intern Med. 1996; 156:259-64. http://www.ncbi.nlm.nih.gov/pubmed/8572835?dopt=AbstractPlus

135. Florence JA, Yeager BF. Treatment of type 2 diabetes mellitus. Am Fam Physician. 1999; 59:2835-44. http://www.ncbi.nlm.nih.gov/pubmed/10348076?dopt=AbstractPlus

136. Yki-Jarvinen H, Dressler A, Ziemen M et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime HPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000; 23:1130-6 (IDIS 451244) http://www.ncbi.nlm.nih.gov/pubmed/10937510?dopt=AbstractPlus

137. Bastyr EJ, Johnson ME, Trautman ME et al. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther. 1999; 21:1703-4. http://www.ncbi.nlm.nih.gov/pubmed/10566566?dopt=AbstractPlus

138. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999; 131:281-303. http://www.ncbi.nlm.nih.gov/pubmed/10454950?dopt=AbstractPlus

139. Pugh JA, Ramirez G, Wagner ML et al. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes Care. 1992; 15:953-9. http://www.ncbi.nlm.nih.gov/pubmed/1387073?dopt=AbstractPlus

140. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Safety. 1994; 11:223-41. http://www.ncbi.nlm.nih.gov/pubmed/7848543?dopt=AbstractPlus

141. Eli Lilly and Company. Humalog (insulin lispro, rDNA origin) injection prescribing information. Indianapolis, IN; 2000 May 1.

142. Haffner SM, Hanefeld M, Fischer S et al. Glibenclamide, but not acarbose, increase leptin concentrations parallel to changes in insulin in subjects with NIDDM. Diabetes Care. 1997; 20: 1430-4. http://www.ncbi.nlm.nih.gov/pubmed/9283792?dopt=AbstractPlus

143. Shi H, Moustaid-Moussa N, Wilkison WO et al. Role of the sulfonylurea receptor in regulating human adipocyte metabolism. FASEB J. 1999; 13:1833-8. http://www.ncbi.nlm.nih.gov/pubmed/10506587?dopt=AbstractPlus

144. Cheskin LJ, Bartlett SJ, Zayas R et al. Prescription medications: a modifiable contributor to obesity. South Med J. 1999; 92:898-904. http://www.ncbi.nlm.nih.gov/pubmed/10498166?dopt=AbstractPlus

145. United Kingdom prospective diabetes study group. United Kingdom prospective diabetes study (UKPDS) 16: overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995; 44:1240-58.

146. Bailey C, Turner R. Metformin. N Engl J Med. 1996; 334:374-9. http://www.ncbi.nlm.nih.gov/pubmed/8538710?dopt=AbstractPlus

147. Clark CM Jr. Where do we go from here? Ann Intern Med. 1996; 124(1 Part 2):184-6. Editorial.

148. Bloomgarden ZT. New and traditional treatment of glycemia in NIDDM. Diabetes Care. 1996; 19:295-9. http://www.ncbi.nlm.nih.gov/pubmed/8742586?dopt=AbstractPlus

149. Anon. Diabetes mellitus. NIH Cons Dev Conf Statement. 1986; 6:1-7.

150. Blake GH. Control of type II diabetes: reaping the rewards of exercise and weight loss. Postgrad Med. 1992; 92:129-32. http://www.ncbi.nlm.nih.gov/pubmed/1437899?dopt=AbstractPlus

151. Kerr CP. Improving outcomes in diabetes: a review of the outpatient care of NIDDM patients. J Fam Pract. 1995; 40:63-75. http://www.ncbi.nlm.nih.gov/pubmed/7807040?dopt=AbstractPlus

152. Turner R, Cull C, Holman R et al. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996; 124(1 Pt 2):136-45. http://www.ncbi.nlm.nih.gov/pubmed/8554206?dopt=AbstractPlus

153. Bristol-Myers Squibb. Metaglip (glipizide and metformin hydrochloride) prescribing information. Princeton, NJ; 2002 Oct.

154. Takeda Pharmaceuticals America. Actos (pioglitazone hydrochloride) tablets prescribing information. Lincolnshire, IL; 2002 July.

155. SmithKline Beecham. Avandia (rosiglitazone maleate) tablets prescribing information. Philadelphia, PA; 2002 May

156. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002; 287:2563-9. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2622728&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/12020338?dopt=AbstractPlus

157. Wolffenbuttel BHR, Gomist R, Squatrito S et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med. 2000; 17:40-7. http://www.ncbi.nlm.nih.gov/pubmed/10691158?dopt=AbstractPlus

158. Kipnes MS, Krosnick a, Rendell MS et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001; 111:10-7. http://www.ncbi.nlm.nih.gov/pubmed/11448655?dopt=AbstractPlus

159. Chiasson J, Josse R, Hunt J et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med. 1994; 121:929-935.

160. Coniff RF, Shapiro JA, Seaton TB et al. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med. 1995; 98:443-51. http://www.ncbi.nlm.nih.gov/pubmed/7733122?dopt=AbstractPlus

161. Calle-Pascual AL, Garcia-Honduvilla J, Martin-Alvarez PJ et al. Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment. Diabetes Metab. 1995; 21:256-60.

162. Klein W. Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy. Diab Metab. 1991; 17(Suppl 1):235-40.

163. Salter F (Bristol Myers Squibb, Princeton, NJ): Personal communication; 2003 Jan 3.

164. Bristol-Myers-Squibb Company. Glucovance(glyburide and metformin hydrochloride) tablets prescribing information. Princeton, NJ; 2000 2002 AugOct.

165. Pfizer. Diflucan (fluconazole) tablets, for oral suspension, and injection prescribing information. New York, NY; 1998 Jun.

166. Hermann LS, Scherstén B, Bitzén PO et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. Diabetes Care. 1994; 17:1100-9. http://www.ncbi.nlm.nih.gov/pubmed/7821128?dopt=AbstractPlus

167. Hermann L. Biguanides and sulfonylureas as combination therapy in NIDDM. Diabetes Care. 1990; 13:37-41. http://www.ncbi.nlm.nih.gov/pubmed/2209342?dopt=AbstractPlus

168. Hermann LS, Melander A. Biguanides: basic aspects and clinical use. In: Alberti KGMM, DeFronzo RA, Keen H et al, eds. International textbook of diabetes mellitus. New York: John Wiley & Sons; 1992; 773-95.

169. Moses R, Carter J, Slobodniuk R et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999; 22:119-24. http://www.ncbi.nlm.nih.gov/pubmed/10333912?dopt=AbstractPlus

170. Fonseca V,, Rosenstock J, Patwardhan R et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000; 283:1695-702. http://www.ncbi.nlm.nih.gov/pubmed/10755495?dopt=AbstractPlus

171. Bristol-Myers Squibb. Glucophage (metformin hydrochloride) tablets and Glucophage XR (metformin hydrochloride) extended-release tablets prescribing information. Princeton, NJ; 2001 Jun.

698. Garber AJ, Handelsman Y, Grunberger G et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm 2020 executive summary. Endocr Pract. 2020; 26:107-139. http://www.ncbi.nlm.nih.gov/pubmed/32022600?dopt=AbstractPlus

699. Zelniker TA, Wiviott SD, Raz I et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019; 139(17):2022-2031. http://www.ncbi.nlm.nih.gov/pubmed/30786725?dopt=AbstractPlus

704. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020; 43:S98-S110. http://www.ncbi.nlm.nih.gov/pubmed/31862752?dopt=AbstractPlus

705. American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020; 43:S111-S134. http://www.ncbi.nlm.nih.gov/pubmed/31862753?dopt=AbstractPlus

706. American Diabetes Association. 11. Microvascular complications and foot care: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020; 43:S135-S151. http://www.ncbi.nlm.nih.gov/pubmed/31862754?dopt=AbstractPlus

707. Pfizer. New York, NY: Personal communication.

Medical Disclaimer